Inter-country variations in anti-asthmatic drug prescriptions for children. Systematic review of studies published during the 2000–2009 period
- 238 Downloads
The objective of this study was to analyse inter-and intra-country quantitative and qualitative differences in anti-asthmatic prescriptions to children and adolescents.
A literature search was performed in EMBASE and MEDLINE to identify pharmaco-epidemiological studies published from January 1, 2000 to December 31, 2008 in which anti-asthmatic prescription prevalence in out-hospital children was measured. A meta-analytic weighted average and 95% confidence intervals of prescription prevalences were calculated using a random-effect(s) model. Inter- and intra-country quantitative and, where possible, qualitative prescribing patterns were compared and assessed.
Twelve studies were identified (ten from Europe, one from Canada and one from the USA), but epidemiological indicators varied widely, and only eight were suitable for meta-analysis. The data from these studies revealed inter-country quantitative differences in prescription prevalences in the overall population ≤19 years, with Italy having a prescription prevalence of 19.0%, Canada, 18.0%, USA, 14.6%, Denmark, 13.9%, Norway, 9.1% and the Netherlands, 6.2%. The overall prevalence was 13.3%. The analysis of qualitative inter-country differences revealed that, except for Italy, inhalatory short-acting β-agonists were the most prescribed, followed by inhalatory corticosteroids.
This first overall analysis of anti-asthmatic utilization studies in out-of-hospital children indicates a wide variability in anti-asthmatic prescription prevalence. It also reveals that epidemiological evaluations should be improved by using homogeneous indicators and, in order to validate the use of anti-asthmatic prescription as a proxy of disease, the diagnosis of asthma should accompany the data of prescriptions within the same population.
KeywordsPharmacoepidemiology Drug utilization studies Anti-asthmatics Childhood asthma
Leukotriene receptor antagonist
Upper respiratory tract infection
The authors are grateful to Dr. Marco Sequi for help in the statistical analysis.
- 1.Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, Williams H (2006) Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 368:733–743CrossRefPubMedGoogle Scholar
- 2.WHO Global Burden Disease (2004) Available at: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html. Accessed 10 June 2009
- 3.Guidelines for the Diagnosis and Management of Asthma (EPR-3) (2007) Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf Accessed 25 June 2009
- 4.British Guideline on the Management of Asthma BTS/SIGN (2008). Available at: http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Asthma/Guidelines/sign101%20revised%20June%2009.pdf Accessed 25 July 2009
- 5.Global Strategy for Asthma Management and Prevention (2008) Available at: http://www.ginasthma.com/GuidelinesResources.asp?l1=2&l2=0 Accessed 15 Jan 2010
- 9.de Vries TW, Tobi H, Schirm E, van den Berg P, Duiverman EJ, de Jong-van den Berg LT (2006) The gap between evidence-based medicine and daily practice in the management of paediatric asthma. A pharmacy-based population study from The Netherlands Eur J Clin Pharmacol 62:51–55Google Scholar
- 18.Kozyrskyj AL, Mustard CA, Becker AB (2004) Identifying children with persistent asthma from health care administrative records. Can Respir J11:141–5.Google Scholar
- 19.Vegni FE, Wilkinson P (2006)Patterns of respiratory drug use in the Lombardy region of Italy, 1995–1997. Eur J Epidemiol 21:537–44.Google Scholar
- 26.Khaled LA, Ahmad F, Brogan T, Fearnley J, Graham J, MacLeod S, McCormick J (2003) Prescription medicine use by one million Canadian children. Pediatr Child Health 8[Suppl A]:6A–56AGoogle Scholar